Joris van Dongen

34 Chapter 2 Table 3. Study characteristics. Name Author Female (F)/ Male (M) Age mean +sd (y) Age variance (y) Liposuction CHA Aronowitz et al. 2013 5F - - Tumescent liposuction CYT LIPOK PNC CYT Aronowitz et al. 2016 5F 32.4 +/-5.9 25-37 Tumescent liposuction GID SVF2 LIPOK PNC LIPOG Bianchi et al. 2013 4 - - Liposuction TGCIS Doi et al. 2012 6F - - Liposuction CYT Domenis et al. 2015 9 46 41-70 Liposuction FAST 6 52 19-74 LIPOK 5 52 41-74 FAT van Dongen et al. 2016 11F - - Liposuction SEPAX Güven et al. 2012 11F - 20-65 Tumescent liposuction CYT Lin et al. 2008 6F 38.7+/-16.3 18-60 Plastic Surgery FEF REF SF Mashiko et al. 2016 10F 41.0+/-8.2 - Liposuction STCELL Millan et al. 3 - - Liposuction SHUF5 Osinga et al. 2015 3F/3M M57, F61 - Liposuction SHUF30 AIS SundarRaj et al. 2015 11 30.86 17-47 - NANO Tonnard et al. 2013 1F 40 n/a Abdominoplasty liposuction AIS Automated Isolation System; CHA-station (CHA-Biotech); CYT Celution System Enzymatic (Cytori); FAST Fastem Corios (Corios); FAT Fractionation of Adipose Tissue procedure; FEF Filtrated fluid of emulsified fat; GID SVF2 (GID Europe); LIPOG Lipogems (Lipogems); LIPOK Lipokit System (Medi-khan); NANO Nanofat procedure; REF Residual tissue of emulsified fat; PNC Multi station (PNC); SEPAX Sepax (Biosafe); SF Squeezed fat; SHUF5 Shuffling 5 times; SHUF30 Shuffling 30 times; STCELL StromaCell; TGCIS Tissue Genesis Cell Isolation System (Tissue Genesis); 1 = used infiltration prior to liposuction, 0 = not mention the use of infiltration or did not use infiltration prior to liposuction